News & Updates

CGRP-targeted therapies herald a new era in migraine management

Calcitonin gene–related peptide (CGRP)–targeted therapies are likely to become a mainstay of migraine headache treatment in the coming decades as they have demonstrated efficacy for acute and preventive treatment, according to Dr Yi-Jing Zhao of Mount Elizabeth Hospital, Singapore, who spoke at AIM 2025.    

Oral, transdermal hormone therapies equally preserve bone health in premature ovarian insufficiency

Hormone therapy, whether administered orally or applied transdermally, helps maintain bone mineral density in women with premature ovarian insufficiency, according to a single-centre retrospective study.

Point-of-care testing detects RTIs faster than ever

Respiratory tract infections (RTIs) have been on the rise post-COVID-19 pandemic.

Due to high patient volumes, delayed clinic presentations, and prolonged lead times for PCR testing in the laboratory, doctors need a rapid and accurate diagnostic tool to help improve in-clinic patient workflow.

Low-fat vegan diet’s alkalizing effect linked to greater weight loss

A low-fat vegan diet yields a significant reduction in dietary acid load compared with the Mediterranean diet, and this alkalizing effect is associated with weight loss in overweight adults, according to the results of a cross-over study.

Novel adaptor enhances care for patients on NIV

A new tube and inhaler adaptor (TIA) has been developed to improve the management of patients receiving noninvasive ventilation (NIV), and this device can be used across diverse clinical settings.

Depression tied to increased mortality in IPF

Patients with idiopathic pulmonary fibrosis (IPF) and comorbid depression are less likely to initiate antifibrotic treatment and thus face an increased risk of death, as reported in a study.

CYP2C19 tied to voriconazole-related adverse reactions in kids

Carriers of the CYP2C19 allele are at greater risk of voriconazole-induced thrombocytopenia and cholestasis, reports a Japan study.

Nerandomilast safe, effective in autoimmune disease-related PPF

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

An empirical dosage of approximately 50 mg/kg on the first day of vancomycin therapy is needed to achieve an area under the concentration-time curve (AUC) in the first 24 h (AUCf24h), suggests a study while noting the use of two-point sampling in Bayesian estimations to improve accuracy.